JP2020120660A5 - - Google Patents

Download PDF

Info

Publication number
JP2020120660A5
JP2020120660A5 JP2020051899A JP2020051899A JP2020120660A5 JP 2020120660 A5 JP2020120660 A5 JP 2020120660A5 JP 2020051899 A JP2020051899 A JP 2020051899A JP 2020051899 A JP2020051899 A JP 2020051899A JP 2020120660 A5 JP2020120660 A5 JP 2020120660A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020051899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020120660A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020120660A publication Critical patent/JP2020120660A/ja
Publication of JP2020120660A5 publication Critical patent/JP2020120660A5/ja
Pending legal-status Critical Current

Links

JP2020051899A 2017-03-27 2020-03-23 キメラ抗原受容体 Pending JP2020120660A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017061461 2017-03-27
JP2017061461 2017-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019509826A Division JP6761113B2 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体

Publications (2)

Publication Number Publication Date
JP2020120660A JP2020120660A (ja) 2020-08-13
JP2020120660A5 true JP2020120660A5 (enExample) 2021-05-13

Family

ID=63676179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019509826A Active JP6761113B2 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体
JP2020051899A Pending JP2020120660A (ja) 2017-03-27 2020-03-23 キメラ抗原受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019509826A Active JP6761113B2 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体

Country Status (16)

Country Link
US (2) US20210122831A1 (enExample)
EP (2) EP4495141A3 (enExample)
JP (2) JP6761113B2 (enExample)
KR (1) KR102333377B1 (enExample)
CN (2) CN116874608A (enExample)
AU (1) AU2018242408B2 (enExample)
BR (1) BR112019019941B1 (enExample)
CA (1) CA3057811A1 (enExample)
CL (1) CL2019002715A1 (enExample)
IL (1) IL269515B2 (enExample)
MX (1) MX2019011404A (enExample)
RU (1) RU2770002C2 (enExample)
SG (1) SG11201908659RA (enExample)
TW (1) TWI753141B (enExample)
WO (1) WO2018181207A1 (enExample)
ZA (1) ZA201906321B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286813A (zh) * 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
WO2020175366A1 (ja) * 2019-02-25 2020-09-03 国立大学法人東京医科歯科大学 キメラ抗原受容体
CN110669144B (zh) * 2019-10-12 2021-09-17 华夏源(上海)细胞基因工程股份有限公司 一种靶向b细胞成熟抗原的嵌合抗原受体及其应用
CN110684739B (zh) * 2019-11-11 2022-05-27 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其应用
CN112608902B (zh) * 2020-12-21 2024-07-02 广东昭泰细胞生物科技有限公司 一种第四代car-t细胞及其应用
WO2022251070A1 (en) * 2021-05-27 2022-12-01 Innovative Cellular Therapeutics Holdings, Ltd. Modified chimeric antigen receptor and use thereof
US20250121002A1 (en) 2021-07-16 2025-04-17 Noile-Immune Biotech Inc. ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
CN117813384A (zh) 2021-07-16 2024-04-02 诺伊尔免疫生物科技株式会社 嵌合抗原受体、表达前述受体的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述嵌合抗原受体的碱基序列的多核苷酸或载体
WO2025096443A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors targeting monosialoganglioside gm2 and methods of use thereof
WO2025096441A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Ganglioside gm2 as a target for cancer immunotherapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014477A1 (en) * 1996-10-04 1998-04-09 Human Genome Sciences, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES WITH LEUKOCYTE ADHESION INHIBITOR-1 (LAI-1), AND CHEMOKINE BETA-11 (Ckβ-11)
AU7449200A (en) * 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20090028877A1 (en) * 2003-10-09 2009-01-29 Shigeru Iida Antibody Composition Specifically Binding to Ganglioside Gm
WO2012033885A1 (en) * 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
CA2851795C (en) * 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN105025923B (zh) * 2012-12-06 2018-03-27 国立大学法人金泽大学 间皮瘤的治疗方法
CA3185368A1 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t cells derived from pluripotent stem cells
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
ME03407B (me) * 2014-04-01 2020-01-20 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Klaudin-6 specifični imunoreceptori i t-ćelijsкi epitopi
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
ES2928000T3 (es) * 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
EP3587446A1 (en) * 2014-09-19 2020-01-01 City of Hope Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
MX358472B (es) * 2014-10-09 2018-08-21 Univ Yamaguchi Vector de expresion de receptor de antigeno quimerico (car) y celulas t que expresan car.
KR20160056228A (ko) 2014-11-11 2016-05-19 주식회사 산내들 견과류의 껍질 분리 회수장치
RU2754041C2 (ru) * 2015-04-03 2021-08-25 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида afp/мнс, и виды их использования
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
KR101873201B1 (ko) * 2015-06-11 2018-07-02 주식회사 제넥신 변형된 인터루킨-7 단백질 및 이의 용도
JP2018522833A (ja) * 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療
EP3320773B9 (en) * 2015-07-10 2023-10-11 Chugai Seiyaku Kabushiki Kaisha Mouse having human cd3 gene substituted for endogenous cd3 gene
KR20180040706A (ko) * 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
WO2017159736A1 (ja) * 2016-03-17 2017-09-21 国立大学法人山口大学 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
AU2020406083A1 (en) * 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant

Similar Documents

Publication Publication Date Title
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2021185136A5 (enExample)
JP2021169491A5 (enExample)
JP2022068302A5 (enExample)
JP2021028398A5 (enExample)
JP2023116721A5 (enExample)
JP2021038271A5 (enExample)
JP2021184963A5 (enExample)
JP2023022224A5 (enExample)
JP2024059739A5 (enExample)
JP2020127428A5 (enExample)
JP2020042034A5 (enExample)
JP2024016014A5 (enExample)
JP2020530297A5 (enExample)
JP2019099571A5 (enExample)
JP2019030304A5 (enExample)
JP2021502066A5 (enExample)
JP2022060295A5 (enExample)
JP2023100643A5 (enExample)
JP2020120660A5 (enExample)
JP2018154848A5 (enExample)
JP2019031552A5 (enExample)
JP2020171301A5 (enExample)
JP2022022379A5 (enExample)